ヒトパピローマウイルス感染症(Human Papillomavirus Infections)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus Infections Overview 9
Therapeutics Development 10
Pipeline Products for Human Papillomavirus Infections – Overview 10
Pipeline Products for Human Papillomavirus Infections – Comparative Analysis 11
Human Papillomavirus Infections – Therapeutics under Development by Companies 12
Human Papillomavirus Infections – Therapeutics under Investigation by Universities/Institutes 16
Human Papillomavirus Infections – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Human Papillomavirus Infections – Products under Development by Companies 20
Human Papillomavirus Infections – Products under Investigation by Universities/Institutes 23
Human Papillomavirus Infections – Companies Involved in Therapeutics Development 24
3M Drug Delivery Systems 24
Admedus Ltd 25
Agilvax, Inc. 26
Anaconda Pharma 27
Beijing Minhai Biotechnology Co., Ltd 28
Bharat Biotech International Limited 29
Biogenomics Limited 30
BioMAS Ltd. 31
Chong Kun Dang Pharmaceutical Corp. 32
Chongqing Zhifei Biological Products Co., Ltd. 33
Crucell N.V. 34
Cutanea Life Sciences 35
EpiPharm AG 36
FluGen, Inc. 37
Foamix Pharmaceuticals Ltd. 38
G&E Herbal Biotechnology Co., Ltd. 39
Genticel S.A. 40
Helix BioPharma Corp. 41
Immunservice GmbH 42
Indian Immunologicals Limited 43
LEO Pharma A/S 44
MediGene AG 45
NanoViricides, Inc. 46
Nielsen Biosciences, Inc. 47
Novan, Inc. 48
Shanghai Zerun Biotechnology Co., Ltd. 49
Spider Biotech 50
Starpharma Holdings Limited 51
Takeda Pharmaceutical Company Limited 52
Vaxart, Inc. 53
ViroStatics, srl 54
Human Papillomavirus Infections – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(digoxin + furosemide) – Drug Profile 65
854-A – Drug Profile 66
A-101 – Drug Profile 67
AP-611074 – Drug Profile 68
AS-101 – Drug Profile 69
astodrimer – Drug Profile 71
AV2-DM – Drug Profile 73
AX-03 – Drug Profile 74
Candida Albicans Antigen – Drug Profile 75
Cell Therapy for Human Papillomavirus Infection – Drug Profile 76
CKD-12201 – Drug Profile 77
Drugs for HPV – Drug Profile 78
EPI-N06 – Drug Profile 79
GBV-015 – Drug Profile 80
HerpeCide-I – Drug Profile 81
HPV virus like particle vaccine – Drug Profile 82
HTI-1968 – Drug Profile 83
human papilloma virus [types 16, 18] (bivalent) virus like particle vaccine – Drug Profile 84
human papilloma virus vaccine – Drug Profile 85
human papilloma virus vaccine – Drug Profile 86
human papilloma virus vaccine [types 16 and 18] – Drug Profile 87
human papillomavirus (multivalent) vaccine – Drug Profile 88
human papillomavirus (tetravalent) vaccine – Drug Profile 89
human papillomavirus [serotypes 16, 31] virus like particle vaccine – Drug Profile 90
human papillomavirus vaccine – Drug Profile 91
human papillomavirus vaccine – Drug Profile 92
human papillomavirus vaccine – Drug Profile 93
human papillomavirus vaccine – Drug Profile 94
human papillomavirus vaccine – Drug Profile 95
human papillomavirus vaccine – Drug Profile 96
human papillomavirus vaccine – Drug Profile 97
human papillomavirus vaccine – Drug Profile 98
imiquimod – Drug Profile 99
ingenol mebutate – Drug Profile 100
interferon alfa-2b (recombinant) – Drug Profile 102
interferon alpha-2b (recombinant) – Drug Profile 103
ISANIL-01 – Drug Profile 104
PL-202 – Drug Profile 105
PP-210 – Drug Profile 106
ProCervix – Drug Profile 107
RKP-00156 – Drug Profile 109
SB-206 – Drug Profile 110
SB105-A10 – Drug Profile 111
sinecatechins – Drug Profile 113
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts – Drug Profile 114
Small Molecules for HPV Infections – Drug Profile 115
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections – Drug Profile 117
SRT-100 – Drug Profile 118
Synthetic Peptides for Viral Infections – Drug Profile 120
Human Papillomavirus Infections – Recent Pipeline Updates 121
Human Papillomavirus Infections – Dormant Projects 129
Human Papillomavirus Infections – Discontinued Products 133
Human Papillomavirus Infections – Product Development Milestones 134
Featured News & Press Releases 134
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141